Microsoft word - final programme

Wednesday 4th
Thursday 5th
Friday 6th
Saturday 7th
MUCUS AND
NON-PYLORI AND
EFFECTIVE H.
EXTRACELLULAR
EXTRA-GASTRIC
PYLORI VACCINE
MANIFESTATIONS
David Thornton:
F. Haesebrouck:
Markus Gerhard
Abstract
Abstract
Phil Sutton
presentations
presentations
ADHESION AND
“- OMICS”
SCIENTIST
VIRULENCE
P. O’Toole:
Presentation by
Laurent Terradot:
award winners.
Abstract
Abstract
presentations
A. van Vliet:
presentations
Poster round 1
Poster round 3
Poster round 2
Poster round 4
INFLAMMATION
CARCINOGENESIS
AND IMMUNITY
AND STEM CELLS
In Memoriam of
Tony Moran
Anne Müller:
Abstract
presentations
Abstract
presentations
T. Wadström:
RESPONSE AND
MECHANISMS
Anthony A. Moran VACCINES
Memorial Lecture: Chair: J Solnick &
Ben Appelmelk:
G. Vasta:
Jay Solnick:
Abstract
presentations
Abstract
Abstract
presentations
presentations
Wednesday July 4, 2012
Poster set up and registration
Welcome address
Leif Percival Andersen, Copenhagen, Denmark In memoriam of Anthony Moran, Ireland
Chair: Sebastian Suerbaum, Germany & Leif P. Andersen, Denmark
Manfred Kist, Freiburg, Germany
Torkel Wadström, Lund, Sweden
The Anthony Moran memorial lecture
Ben Appelmelk, Amsterdam, the Netherlands
HP-33 Warren Flood, Manchester, UK
Analysis of the role of O-antigen adhesion to DC-SIGN and galectin-3 in the immune response to Helicobacter pylori Horemans, Wilrijk, Belgium
In vitro and in vivo evaluation of the anti-adhesive effect of milk fat globule membrane glycoproteins on Helicobacter pylori HP-48 Ana Magalhães, Porto, Portugal
Helicobacter pylori switches the host cells glycosylation pathways to remodel the gastric mucosa glycophenotype. Poster viewing etc.
Business meeting for committees. Room B-21.
Thursday July 5, 2012
Session 1. Mucus and extracellular matrix
Chair: Sara Lindén, Sweden & Karen Robinson, UK
David Thornton, Manchester, UK:
The role of the mucus barrier in protection against infection with intestinal
dwelling nematodes
HP-04 Emma Skoog, Gothenburg, Sweden
Human gastric mucins differently regulate Helicobacter pylori proliferation, gene expression and interactions with host cells Navabi, Gothenburg, Sweden
Helicobacter pylori infection impair mucin production rate and turn over in the murine gastric mucosa Alvarez, SP, Brazil
Promoter hypermethylation of multiple genes in association with early stage of H. pylori infection Behrens, Hannover, Germany
Role of the proposed Helicobacter pylori energy sensor TlpD in vivo and characterization of protein-protein interactions of TlpD Bugaytsova, Umeå, Sweden
Polymorphism and adaptation in pH-regulated H. pylori adherence 10.00 Break
Thursday July 5, 2012
Session 2: Adhesion and virulence factors
Chair: Thomas Boren, Sweden & Rainer Haas, Germany
Laurent Terradot, Lyon, France
Towards the structural basis of CagA translocation HP-01 Sarah Schätzle, Freiburg, Germany
Helicobacter pylori possesses 4 coiled coil rich proteins (Ccrp) that form extended filamentous structures and control cell shape and motility HP-23 Silja Wessler, Salzburg, Austria
HtrA: a new secreted virulence factor in bacterial infections HP-25 Luisa F. Jiménez-Soto, Munich, Germany
Induction of host cell resistance to CagA translocation of Helicobacter pylori by co-incubation experiments HP-37 Marta Justino, Oeiras, Portugal
NorH, the first nitric oxide reductase of Helicobacter pylori HP-39 Christina Josenhans, Hannover, Germany
The H. pylori cagPAI expresses a novel effector-like protein which targets human ubiquitin and related small modifiers 12.00 Lunch
Thursday July 5, 2012
Poster session 1: Colonization and virulence factors
Chair: Torkel Wadström, Sweden & Christine Josenhans, Germany
HP-02 Sara Lindén, Gothenburg, Sweden
Gastrointestinal in vitro models for infection studies resembling the in vivo human gastrointestinal tract. Alvarez, SP, Brazil
Effect of H. pylori infection on GATA 5 and TFF1 regulation, in vivo and in vitro evidences HP-22 Annemieke Smet, Ghent, Belgium
Gastric mucin alterations associated with H. heilmannii sensu stricto infection Flahou, Ghent, Belgium
Helicobacter suis outer membrane vesicles and their influence on gastric epithelial cells HP-59 Zahra Pakbaz, Tehran, Iran
Frequency of sialic acid binding adhesion gene in Helicobacter pylori isolated from patient with gastroduodenal diseases HP-60 Zahra Pakbaz, Tehran, Iran
Clinical prevalence of the Helicobacter pylori gene for blood-group antigen-binding adhesion HP-74 Ebenezer K Aidoo, Korle-Bu, Ghana
Helicobacter pylori vacA and cagA related genes from diseases of the stomach at the Korle-Bu Teaching Hospital, Accra, Ghana HP-82 Jody Winter, Nottingham, UK
VacA enhances immunomodulatory effects of Helicobacter pylori membrane vesicles HP-86 Sushil Kumar Pathak, Stockholm, Sweden
The role of Helicobacter pylori secreted virulence factor JHP290 in disease development HP-88 Lone Rasmussen, Copenhagen, Denmark
Development of a novel assay for quantification of Helicobacter pylori cell adhesion Thursday July 5, 2012
Poster session 2: Inflammation, immunology and vaccines
Chair: Mario D’Elios, Italy & Dionyssios Sgouras, Greece
HP-12 Anne Müller, Zurich, Switzerland
Systemic immunomodulation by Helicobacter pylori protects against allergic and chronic inflammatory disorders via tolerogenic re-programming of dendritic cells Walduck,
Melbourne, Australia
Leptin receptor signaling is an important regulator of both CD4+ T cell and Treg function in the gastric mucosa Melbourne, Australia
Immune cell protease activated Receptor 1 suppresses the cytokine and vaccine-induced protective response to Helicobacter pylori Raghavan, Gothenburg, Sweden
Transient depletion of regulatory T cells in the transgenic mice enhances local immune responses to Helicobacter pylori infection HP-49 Richard Ingram, Nottingham, UK
Luminex® assay optimisation: a novel approach to characterising cytokine expression profiles in human gastric biopsies in Helicobacter pylori infection HP-50 Emily Staples, Nottingham, UK
Are Th17 or Th1 cells dominant in human Helicobacter pylori infection? Ottsjö, Gothenburg, Sweden
Differentiating roles for interferon-γ and IL-17 in protection against Helicobacter pylori infection HP-61 Ziba Malekshahi, Tehran, Iran
Analysis of comparative effect of IgY produced against UreC protein and UreC DNA vaccine on H. pylori infection in mice Sundus, Munich, Germany
Helicobacter γGT dependent pathogenesis of epithelial cells HP-79 Manuel Koch, Berlin, Germany
Induction of miR-155 by Helicobacter pylori inhibits DNA-damage induced apoptosis HP-83 Florian Anderl, Munich, Germany
Therapeutic efficacy of a Helicobacter pylori vaccine dependent on antibodies and T-cells Thursday July 5, 2012
Session 3: Inflammation and immunity
Chair: John Nedrud, USA & Phil Sutton, Australia
Anne Müller, Zurich, Switzerland
Helicobacter pylori targets dendritic cells to induce immune tolerance, promote
persistence and confer protection against allergic asthma.
HP-11 Katherine W. Cook, Nottingham, UK
Gastric migration of regulatory T-cells, mediated via the chemokine CCL20 and its receptor CCR6, in Helicobacter pylori infected humans and mice HP-13 Stefanie Wüstner, Munich, Germany
Helicobacter γ-glutamyltranspeptidase inhibits T cell proliferation via glutamine depletion HP-46 Anzel Borgel Greenaway, Nottingham, UK
Identification of immunomodulatory molecules from Helicobacter pylori, and their role during infection HP-69 Raphaela Semper, Munich, Germany
Involvement of the inflammasome in infection with Helicobacter pylori HP-72 Raquel Mejias-Luque, Munich, Germany
Helicobacter pylori induces LTβR signaling in gastric cells 15.30 Break
Thursday July 5, 2012
Session 4: Immune response and vaccines
Chair: Jay Solnick, USA & Samuel Lundin, Sweden
Jay Solnick, Davis, CA, USA
Individual differences and the outcome of infectious diseases HP-03 Dominique Velin, Lausanne, Switzerland
PAR2 promotes vaccine-induced protection against Helicobacter infection in mice HP-09 Miet Vermoote, Ghent, Belgium
Protective efficacy of recombinant Helicobacter suis proteins against Helicobacter suis challenge in a mouse model HP-42 Alma Fulurija, Western Australia, Australia
Helicobacter pylori platform technology (HPPT) for vaccine delivery: Phase I safety and immunogenicity data of candidate H. pylori recipient strains Rakhimova, Umeå, Sweden
Mucosal immunization with H. pylori adhesins confers therapeutic immunity in primates 18.00 Dinner
Buses are leaving for Frederiksborg Castle
Friday July 6, 2012
Session 5: Non pylori and extra gastric manifestations
Chair: Freddy Haesebrouck, Belgium & Hazel Mitchell, Australia
Freddy Haesebrouck, Gent, Belgium
New insights in gastric non-Helicobacter pylori helicobacters HP-07 Pradeep Kondadi, Helsinki, Finland
The putative contingency nature of Helicobacter bizzozeronii NAD(P)H-nitroreductase HBZC1_00960 HP-27 Annemieke Smet, Ghent, Belgium
Colonization capacity of Helicobacter heilmannii sensu stricto isolates in a Mongolian gerbil model Flahou, Ghent, Belgium
Modulation of Helicobacter suis-induced inflammation by glutamine and reduced glutathione HP-34 Ines Yang, Hannover, Germany
Susceptibility of IL-10 deficient mice to Helicobacter hepaticus-induced colitis depends on intestinal microbiota composition HP-64 Hazel Mitchell, New South Wales, Australia
Helicobacter pullorum - A potential gastrointestinal pathogen? 10.00 Break
Friday July 6, 2012
10.30 Session
“-OMICS”
Chair: Arnoud van Vliet, UK & Sebastian Suerbaum, Germany
Paul O’Toole, Cork, Ireland
HP-06 Ichizo Kobayashi, Tokyo, Japan
Genome-wide survey of mutual homologous recombination in H. pylori HP-08 Mirko Rossi, Helsinki, Finland
Genomics and microevolution dynamics of human-derived Helicobacter bizzozeronii HP-14 Juliane Krebes, Hannover, Germany
The nucleotide excision repair (NER) system of Helicobacter pylori: Role in mutation prevention and chromosomal import patterns after natural transformation Sharma, Würzburg, Germany
Small regulatory RNAs in Helicobacter pylori and Campylobacter jejuni HP-75 Selva Parumal Gunaletchumy, Kuala Lumpur, Malaysia
Genomic structure and diversity of Helicobacter pylori strains from Malaysia 12.00 Lunch
Friday July 6, 2012
Poster session 3: OMICS and extra gastric manifestations
Hilde DeReuse, France & Henrik Permin, Denmark HP-10 Jonathan
Gauntlett,
Western Australia, Australia
Xer-cise for markerless gene deletions in H. pylori HP-17 Lynn Kennemann, Hannover, Germany
In vivo sequence variation in HopZ, a phase variable outer membrane protein of Helicobacter pylori HP-21 Marcelo Ribeiro, SP, Brazil
Effects of Helicobacter pylori infection on MGMT and MLH1 promoter methylation status and microsatellite instability in paediatric and adult patients Flahou, Ghent, Belgium
Helicobacter suis infection in a pig veterinarian Flahou, Ghent, Belgium
Presence of viable Helicobacter suis bacteria in pork HP-62 Ziba Vaise Malekshahi, Tehran, Iran
Helicobacter pylori infection in mice HP-67 Hazel Mitchell, New South Wales, Australia
Microbial dysbiosis in pediatric patients with Crohn’s disease HP-71 Yalda Khosravi, Kuala Lumpur, Malaysia
In vitro study of Helicobacter pylori interspecies interaction HP-73 Arnoud van Vliet, Norwich, UK
Transcriptional features are rewired during genome evolution in the Epsilon-Proteobacteria HP-77 Amin Abadi, Tehran, Iran
Extremely susceptibility of H. pylori to moxafloxacine as one of newly introduced fluroquinolones HP-78 Amin Abadi, Tehran, Iran
Clinical value of HopQI genotype of Helicobacter pylori; association with resistance phenomena HP-85 Ceara de Lacy Clancy, Cork, Ireland
Comparative genomic analysis of the Helicobacter pylori strains 17874 and P79 HP-87 Nele de Klerk, Stockholm, Sweden
Interaction between urease and AhpC of H. pylori and CD46 HP-89 Elif Dagdan, Berlin, Germany
Meta-analysis of microarrays to identify modification in host cells upon infection by Helicobacter pylori Friday July 6, 2012
Poster session 4: Basic mechanisms and carcinogenesis
Markus Gerhardt, Germany & Ming Chen, Denmark. HP-26 Eliette Touati, Paris, France
Consequences of Helicobacter pylori infection on mitochondria and their genome, relation with gastric pathogenesis Formichella, Munich, Germany
A novel line blot system to detect an infection with pathogenic H. pylori Rivera-Ordaz, Munich, Germany
L-prolyne transport and metabolism in Helicobacter pylori physiology HP-63 Nazar Abdalsadeg, Omdurman, Sudan
Molecular characterization of clarithromycin-resistant Helicobacter pylori among dyspeptic patients in Khartoum State HP-65 Hazel Mitchell, New South Wales, Australia
PAR-1 polymorphisms and risk of gastric cancer in a Chinese population HP-66 Hazel Mitchell, New South Wales, Australia
Pattern recognition receptors and Helicobacter pylori-related gastric cancer Xinsheng
Kuala Lumpur, Malaysia
Changing Helicobacter pylori antibiotic resistance pattern in Malaysia HP-76 Amin Abadi, Tehran, Iran
Combined presence of the Helicobacter pylori jhp0562 and tnpA genes predict the presence of duodenal ulcer HP-80 Birgitte Smith, Copenhagen, Denmark
Esomeprazole treatment of type 2 diabetes patients decreased levels of H. pylori and raised HbA1c levels HP-81 Bow Ho, Singapore
Galectin 3 and ERK activation - A cross talk event of signal transduction in H. pylori infected cells HP-84 Ceara de Lacy Clancy, Cork, Ireland
Investigation of the interaction node of the Helicobacter pylori flagellum biogenesis protein HP0958 Friday July 6, 2012
Session 7: Carcinogenesis and stem cells
Chair: Gabrielle Rieder & Johan Wandall, Denmark
John Nedrud, Cleveland, USA
H. pylori infection promotes intestinal inflammation and colon carcinogenesis
in mice deficient in T cell SMAD4
HP-18 Gabrielle Rieder, Salzburg, Austria
A bacterial host CagL/avß5 integrin complex is responsible for Helicobacter pylori-induced precancerous condition HP-20 Juliana Santos, SP, Brazil
Evaluation of gene expression profile of chromatin modification enzymes in ACP02 and ACP03 gastric cell lines Hartung, Zurich, Switzerland
The carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double strand breaks and a DNA damage response in infected host cells Alpízar-Alpízar, Copenhagen, Denmark
Urokinase plasminogen activator receptor (uPAR) is upregulated in gastric mucosa in response to Helicobacter pylori infection in C57BL/6 mice HP-51 Vânia Camilo, Porto, Portugal
Helicobacter pylori and the BMP pathway regulate CDX2 and SOX2 expression in gastric cells 15.30 Coffee
Friday July 6, 2012
Session 8: Basic Mechanisms
Chair: Karen Krogfelt, Denmark & Bow Ho, Singapore
Gerardo Vasta, Baltimore, USA
The sweet tooth of innateimmunity: The first barrier or the Trojan horse? HP-32 Hilde de Reuse, Paris, France
Post-transcriptional control of gene expression in Helicobacter pylori: major role of the RNase J ribonuclease that is associated with the sole DExD-box RNA-helicase into an RNA-degradosome HP-38 Margarida Parente, Oeiras, Portugal
The nitroreductase FrxA protects Helicobacter pylori from nitrosative injury HP-43 K. Papadakos, Athens, Greece
Involvement of CagA EPIYA phosphorylation in the induction of IL-8 through the activation of TAK1 kinase HP-57 Sandy Pernitzsch, Würzburg, Germany
A small regulatory RNA represses expression of the chemotaxis receptor TlpB Teymournejad, Tehran, Iran
In vitro suppression of Dendritic cells by Helicobacter pylori OipA 18.00 Dinner
Business meeting for committees and interested participants. Room B-21
Award committee meeting. Room B-21
Live music at Konventum
Saturday July 7, 2012
Session 9: Can we make a truly effective vaccine against H pylori?
Chair: Mario D’Elios, Italy & Hanne Colding, Denmark
Pro Markus Gerhard
Contra Phil Sutton
Johan
Wandall
Chair: Thomas Borén, Sweden & Leif P. Andersen, Denmark
Young Scientist awards (5 min presentations each)
Highlights 2012
Close of the meeting

Source: http://www.helicobacter-helsingor.eu/Program_HPI2012_final.pdf

Material safety data sheet (revised)

Latanoprost Ophthalmic Solution, 0.005% MATERIAL SAFETY DATA SHEET Effective Date: 3/15/11 Supersedes: None Page 1 of 9 Section 1: CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT: Product Name: Latanoprost Ophthalmic Solution, 0.005% Product Code(s): AB46395 NDC No(s): 24208-463-25 (2.5 mL) Intended Use: Pharmaceutical product used for glaucoma Chemical Family

 criminal victimization of persons with severe mental illness

Treatment Advocacy Center Briefing Paper Bipolar disorder (manic-depressive illness) SUMMARY : Bipolar disorder (manic-depressive illness) is a neurobiological brain disorder that affects approximately 2.3 million Americans today, or almost 1 percent of the population. Individuals diagnosed with this disease have mood swings that alternate from periods of severe highs (mania) to extr

Copyright © 2018 Medical Abstracts